Susquehanna International Group
EGRX

Susquehanna International Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Susquehanna International Group’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-30,300
Closed -$159K – 13473
2024
Q1 		$159K Buy
+30,300
New +$166K ﹤0.01% 10849
2020
Q2 		– Sell
-19,200
Closed -$883K – 11127
2020
Q1 		$883K Buy
19,200
+2,700
+16% +$135K ﹤0.01% 5684
2019
Q4 		$991K Buy
16,500
+11,500
+230% +$686K ﹤0.01% 5545
2019
Q3 		$283K Sell
5,000
-92,900
-95% -$5.22M ﹤0.01% 8418
2019
Q2 		$5.45M Buy
97,900
+18,400
+23% +$960K ﹤0.01% 2598
2019
Q1 		$4.01M Buy
79,500
+23,100
+41% +$1.03M ﹤0.01% 2720
2018
Q4 		$2.27M Sell
56,400
-35,300
-38% -$1.82M ﹤0.01% 3344
2018
Q3 		$6.36M Sell
91,700
-8,800
-9% -$667K ﹤0.01% 2390
2018
Q2 		$7.6M Buy
100,500
+28,900
+40% +$1.82M ﹤0.01% 2226
2018
Q1 		$3.77M Buy
71,600
+25,000
+54% +$1.45M ﹤0.01% 2906
2017
Q4 		$2.49M Sell
46,600
-9,300
-17% -$518K ﹤0.01% 3535
2017
Q3 		$3.33M Buy
55,900
+23,700
+74% +$1.43M ﹤0.01% 3071
2017
Q2 		$2.54M Buy
32,200
+21,200
+193% +$1.73M ﹤0.01% 3455
2017
Q1 		$912K Sell
11,000
-53,600
-83% -$3.98M ﹤0.01% 5324
2016
Q4 		$5.13M Buy
64,600
+14,000
+28% +$1.02M ﹤0.01% 2402
2016
Q3 		$3.54M Sell
50,600
-10,000
-17% -$554K ﹤0.01% 2673
2016
Q2 		$2.35M Sell
60,600
-15,100
-20% -$629K ﹤0.01% 3304
2016
Q1 		$3.07M Buy
75,700
+22,900
+43% +$1.45M ﹤0.01% 3024
2015
Q4 		$4.68M Sell
52,800
-32,100
-38% -$2.53M ﹤0.01% 2641
2015
Q3 		$6.29M Buy
84,900
+37,700
+80% +$3.14M ﹤0.01% 2361
2015
Q2 		$3.82M Buy
+47,200
New +$3.07M ﹤0.01% 3407

Other funds holding EGRX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Susquehanna International Group's EGRX Position: Q2 2024 in Review

Susquehanna International Group sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2024, closing a stake of 11,087 shares — an estimated $48.3K sold.

Susquehanna International Group first reported a position in EGRX in Q1 2015 and held it in 24 quarters. The position peaked at $2.93M in Q4 2015. 75 funds tracked by Wall St. Rank hold EGRX as of Q2 2024.

  • Susquehanna International Group reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Susquehanna International Group sold 11,087 Eagle Pharmaceuticals, Inc. shares in Q2 2024, an estimated $48.3K.
  • Susquehanna International Group first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2015 and held it in 24 quarters.
  • Susquehanna International Group's Eagle Pharmaceuticals, Inc. position peaked at $2.93M in Q4 2015.
  • 75 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2024.

Based on Susquehanna International Group's 13F filing for Q2 2024, filed 15 Aug 2024.